News

TEDCO Announces Investment into Astek Diagnostics

TEDCO, Maryland’s economic engine for technology companies, announced a Seed Funds investment of $250,000 into Astek Diagnostics, a life sciences company fighting antibiotic resistance through innovative technology. In addition to this investment through the Life Sciences Investment Fund – a funding opportunity under the umbrella of TEDCO’s Seed Funds – Astek Diagnostics has received an additional $325,000 from the State Small Business Credit Initiative (SSBCI) funding.

Mustafa Al-Adhami“Without the proper diagnostic procedures, patients and physicians risk advancing the vicious cycle of antibiotic resistance,” explained Mustafa Al-Adhami, PhD, CEO of Astek Diagnostics. “This cycle leads to the creation of more resilient bacteria that require more complicated treatments. But with the help of our device, the Jiddu, we can put an end to this disastrous cycle. The Jiddu provides physicians with more diagnostic material, allowing them to make informed decisions about the best prescribing methods to use.”

Astek Diagnostics, based in Baltimore, Md., is a business that is focused on creating a platform to determine antibiotic sensitivity. Through this venture, the company developed the Jiddu. This device is a cost-effective and efficient diagnostic platform that provides physicians with adequate accurate information to diagnose and treat urinary tract infections, finding any antibiotic susceptibility and preventing the use of ineffective or excessive antibiotics—a practice that can cause the creation of antibiotic resistant bacteria.

Astek Diagnostics“The issue of bacteria resiliency affects us all,” said Teddy Gresser, director of Seed Funds at TEDCO. “Astek’s determination to fight against antibiotic resistance has potential to not only be a successful business venture, but also to change the way physicians operate, allowing for more accuracy and less complications. TEDCO is eager to witness Astek Diagnostics’ journey, what innovations they can create, and how their business will impact Maryland.”

Astek is a long-standing TEDCO portfolio company, having received funding from TEDCO’s Pre-Seed Builder Fund, Maryland Innovation Initiative (MII), and successfully participated in TEDCO’s SBIR/STTR Proposal Lab.

The Seed Fund is one of the many funding opportunities available through TEDCO; for information on other opportunities, or information on how to apply, entrepreneurs should visit https://www.tedcomd.com/funding.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation